摘要
达比加群酯是一种直接抑制凝血酶的新型口服抗凝药,具有较好的抗凝疗效和安全性,出血是其最常见的不良反应,发生率略低于或类似于华法林和依诺肝素。当服用达比加群酯的患者发生大出血,或者需进行手术或侵入性处理时,常须紧急逆转其抗凝活性。目前尚未研发出达比加群酯特异性解药,临床上应根据患者的出血部位和严重程度,进行综合治疗。监测凝血酶凝固时间(TT)和蛇静脉酶凝结时间(ECT)等指标有助于判断逆转达比加群酯活性的疗效。
Dabigatran etexilate is a new oral anticoagulant that acts as a direct thrombin inhibitor.Dabigatran etexilate generally shows good efficacy and safty,however,bleeding is the most common side effect which is slightly lower than or similar to that of warfarin or enoxaparin.In certain clinical situations including major bleeding and requirement of surgery or invasive procedure,clinicians will have to reverse the anticoagulant effect of dabigatran etexilate emergently.So far no antidote for dabigatran etexilate has been established.The management of bleeding resulting from dabigatran etexilate should be individualized based on the location and severity of the hemorrhage.Tests including thrombin clotting time（TT） and ecarin clotting time（ECT） will be helpful to determine the reversal of the anticoagulant effect of dabigatran etexilate.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2012年第12期1413-1418,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家高技术研究发展计划(863计划)(2012AA02A517
2012AA02A518)
教育部跨世纪优秀人才培养计划(NCET-10-0843)
湖南省科研基金(11K073
12JJ7006)
关键词
达比加群酯
逆转
抗凝
出血
Dabigatran etexilate
Reversal
Anticoagulant effect
Bleeding
